The actions in this Multidistrict Litigation (“MDL”) (MDL No. 3094) are generally personal injury actions stemming from use of glucagon-like peptide-1 receptor agonists (“GLP-1 RAs”), which are medicines prescribed for, among other things, the treatment of type 2 diabetes. This class of medications includes Ozempic, Wegovy, and Rybelsus, which are manufactured by the Novo Nordisk defendants, and Trulicity and Mounjaro, which are manufactured by Eli Lilly and Company.

     The United States Judicial Panel on Multidistrict Litigation (“MDL Panel”) found that the actions in this MDL “involve common questions of fact, and that centralization in the Eastern District of Pennsylvania will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation.” In so finding, the MDL Panel noted that “[e]ach lawsuit contains substantially similar allegations about GLP-1 RAs (specifically, Ozempic, Wegovy, Rybelsus, Trulicity, and/or Mounjaro) and their alleged propensity to cause gastrointestinal injuries . . . [and] [a]ll actions share common issues of fact regarding whether defendants knew or should have known that their GLP-1 RA products can cause gastroparesis and other gastrointestinal injuries, whether defendants adequately warned plaintiffs or their prescribing physicians about the alleged dangers of these products, and whether defendants made false, misleading, or incomplete representations regarding the safety of these products.” The Novo Nordisk defendants and Eli Lilly and Company deny these allegations.